Eric Luiz Domingos

Eric Luiz Domingos

Auto-generated profile, based on publicly available information

Eric Luiz Domingos

Pharmaceutical Sciences Postgraduate Program, Federal University of Parana, Curitiba, Brazil

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Hazardous Materials
Verified
Journal Article
Closed access
BBBeatriz Böger
Beatriz Böger
MSMonica Surek
Monica Surek
RVRaquel de O Vilhena
Raquel de O Vilhena
MFMariana Millan Fachi
Mariana Millan Fachi
AJAllan M Junkert
Allan M Junkert
RPRoberto Pontarolo
Roberto Pontarolo

1 October 2020 in Ciencia & Saude Coletiva
Verified
Journal Article
Open access
PDF file
ACAlexandre de Fátima Fátima Cobre
Alexandre de Fátima Fátima Cobre
BBBeatriz Böger
Beatriz Böger
MFMariana Millan Fachi
Mariana Millan Fachi
RVRaquel de Oliveira Vilhena
Raquel de Oliveira Vilhena
EDEric Luiz Domingos
Eric Luiz Domingos
RPRoberto Pontarolo
Roberto Pontarolo
We investigated the predictors of delay in the diagnosis and mortality of patients with COVID-19 in Rio de Janeiro, Brazil. A cohort of 3,656 patients were evaluated (Feb-Apr 2020) and patients’ sociodemographic characteristics, and social development index (SDI) were used as determinant factors of diagnosis delays and mortality. Kaplan-Meier survival analyses, time-dependent Cox regression models, and multivariate logistic regression analyses were conducted. The median time from symptoms onset to diagnosis was eight days (interquartile range [IQR] 7.23-8.99 days). Half of the patients recovered during the evaluated period, and 8.3% died. Mortality rates were higher in men. Delays in diagnosis were associated with male gender (p = 0.015) and patients living in low SDI areas (p < 0.001). The age groups statistically associated with death were: 70-79 years, 80-89 years, and 90-99 years. Delays to diagnosis greater than eight days were also risk factors for death. Delays in diagnosis and risk factors for death from COVID-19 were associated with male gender, age under 60 years, and patients living in regions with lower SDI. Delays superior to eight days to diagnosis increased mortality rates.

9 June 2022 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
EDEric L. Domingos
Eric L. Domingos
RVRaquel O. Vilhena
Raquel O. Vilhena
JSJosiane M.M.F. Santos
Josiane M.M.F. Santos
MFMariana Millan Fachi
Mariana Millan Fachi
BBBeatriz Böger
Beatriz Böger
RPRoberto Pontarolo
Roberto Pontarolo

20 February 2020 in Journal of Dermatological Treatment
Verified
Journal Article
Open access
MFMaria L. D. Fávero
Maria L. D. Fávero
ABAline F. Bonetti
Aline F. Bonetti
EDEric L. Domingos
Eric L. Domingos
FTFernanda Tonin
Fernanda Tonin
RPRoberto Pontarolo
Roberto Pontarolo
Toenail fungal infections account for half of all nail disease cases, and a highly negative impact on patient quality of life. Our aim was to compare the efficacy and safety of commercially available oral antifungals for onychomycosis. A systematic review was performed in PubMed and Scopus. Randomized controlled trials evaluating the effect of oral antifungals on mycological cure, discontinuation and adverse events were included. Network meta-analyses were built for each outcome. Results were reported as odds ratios (OR) with 95% credibility intervals (CrI). Ranking probabilities were calculated by surface under the cumulative ranking analysis (SUCRA). We included 40 trials (n = 9568). Albaconazole 400 mg (OR 0.02 [95% CrI 0.01-0.07] versus placebo), followed by posaconazole 200-400 mg and terbinafine 250-350 mg were considered the best therapies (SUCRA probabilities over 75%). For the networks of discontinuation and individual adverse events, few significant differences among treatments were observed, but itraconazole 400mg was considered the safest drug (SUCRA around 25%). Albaconazole 400 mg, posaconazole 200-400 mg, and terbinafine 250-350 mg were the most effective therapies for onychomycosis, while itraconazole 400 mg was the safest. The profile of albaconazole and posaconazole compared to current first-line therapies should be further investigated in well-designed trials.

18 February 2020 in Biomedical Chromatography
Verified
Journal Article
Closed access
PDF file
MFMariana Millan Fachi
Mariana Millan Fachi
RVRaquel Oliveira Vilhena
Raquel Oliveira Vilhena
BBBeatriz Böger
Beatriz Böger
EDEric Luiz Domingos
Eric Luiz Domingos
JSJosiane Marlei Müller Fernandes dos Santos
Josiane Marlei Müller Fernandes dos Santos
RPRoberto Pontarolo
Roberto Pontarolo

5 September 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
JSJosiane M. Santos
Josiane M. Santos
MFMariana Millan Fachi
Mariana Millan Fachi
FBFrancisco Beraldi-Magalhaes
Francisco Beraldi-Magalhaes
BBBeatriz Böger
Beatriz Böger
AJAllan M. Junker
Allan M. Junker
RPRoberto Pontarolo
Roberto Pontarolo